knowledge -WSS

knowledge

author：fashion 2025-09-28 02:26:59 - browse：7

UnitedHealth Group’s Optum subsidiary saw a lower operating margin in the second quarter due to more seniors getting care, a spike in demand for behavioral health services, and an influx of members with higher health needs.

“Those three elements, the senior trend piece, the behavioral piece, and then the effects of the strong growth is really what explains what’s going on,” UnitedHealth Group CEO Andrew Witty said on the company’s earnings call on Friday. “We’ll continue to lean into that growth very assertively.”

Minnetonka, Minn.-based UnitedHealth Group’s Optum segment, which includes its provider arm, its pharmacy benefit manager, and its data and technology arm, reported an operating margin of 6.6% in the quarter ended June 30, compared with 7.3% in the prior-year period. Leaders said the decline was within its provider arm, Optum Health.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Senate panel puts off hardest PBM reforms for another day

WSS

What causes rare myocarditis in young men after Covid vaccines?

Merck, Johnson & Johnson CEOs will testify on high drug prices

Biogen says it will cut costs by $700 million, slash 1,000 jobs

The battle over 'scope creep' and who gets to be called 'doctor'

White House pharmacy plagued with problems, investigation finds

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

hotspot

knowledge

hotspot

Walensky prepares to leave CDC — and Congress — behind

Biogen walks away from Aduhelm, years after polarizing approval

Walensky prepares to leave CDC — and Congress — behind

Biden warns of ‘dark winter’ during final presidental debate

Sports medicine is finally prioritizing gender equality

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Wildfire smoke exposes gaps in outdoor worker protections

Investment in vaccine development is lagging, report finds

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

White House pharmacy plagued with problems, investigation finds

focus

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Humana’s losses in Medicare Advantage tank its stock

Venture capital firm's plans to take over Akron hospital face hurdles

Truvian presents data for its desktop blood

Philips to halt sales of sleep apnea machines in U.S.

Dems pitch expanding Medicare power to negotiate drug prices

explore

focus

hotspot

hotspot